![]() | Up a level |
Heist, R. S., Garon, E. B., Tan, D. S. W., Groen, H. J. M., Seto, T., Smit, E. F., Nwana, N., Fairchild, L., Balbin, A., Yan, M., Wang, I., Giovannini, M., Sankaran, B. and Wolf, J. (2020). Accurate Detection of METex14 Mutations in Non-Small Cell Lung Cancer (NSCLC) with Comprehensive Genomic Sequencing: Results from the GEOMETRY Mono-1 Study. J. Thorac. Oncol., 15 (2). S. S30 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Vansteenkiste, J. F., Smit, E. F., Groen, H. J. M., Garon, E. B., Heist, R. S., Hida, T., Nishio, M., Kokowski, K., Grohe, C., Reguart, N., Mansfield, A. S., Robeva, A., Ghebremariam, S., Waldron-Lynch, M., Akimov, M., Nwana, N., Giovannini, M. and Wolf, J. (2020). Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study. Ann. Oncol., 31. S. S830 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 143 - 144. BASEL: KARGER. ISSN 2296-5262
Wolf, J., Overbeck, T., Han, J. -Y., Hochmair, M., De Marinis, F., Ohashi, K., Smit, E. F., Power, D., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M. and Heist, R. S. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Oncol. Res. Treat., 43 (SUPPL 4). S. 150 - 152. BASEL: KARGER. ISSN 2296-5262